Posted by Michael Wonder on 16 Nov 2017
Janssen announces Health Canada approval of Tremfya (guselkumab) for the treatment of adult moderate to severe plaque psoriasis
15 November 2017 - Tremfya is the first approved biologic that selectively blocks interleukin-23.
Janssen announced today that Health Canada has approved Tremfya (guselkumab) for the treatment of adults living with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Tremfya is the first approved biologic therapy that selectively blocks interleukin-23, a key inflammatory protein that plays an important role in plaque psoriasis.
Tremfya received this approval based on results from two 48 week pivotal phase 3 studies, VOYAGE 1 and VOYAGE 2, which demonstrated significant efficacy in adult patients with moderate to severe plaque psoriasis treated with Tremfya.
